Tardive dyskinesia (TD) is an abnormal involuntary movement disorder that arises as a common adverse effect in patients using antipsychotic medications, occurring in an estimated 20% of this population. This condition inflicts a substantial negative impact on patient quality of life and clinical outcomes and contributes to the significant rate of nonadherence to antipsychotic medication regimens.

Tardive Dyskinesia 360 is a resource center built for mental health practitioners, designed to educate providers on the proper screening, diagnosis, and treatment of TD. Explore expert video commentary, patient cases activities, instructional videos, and stay up to date on the latest information related to TD care.

Tardive Dyskinesia

Video

AIMS Instructional Video

Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia.

From normal (0) to severe (4), see what real tardive dyskinesia movements look like so you can better assess your patients.

Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.

Articles

Once-daily valbenazine was effective and generally well tolerated in adults with tardive dyskinesia who took the drug for up to 48 weeks, according to a study published online in The Journal of Clinical Psychiatry.

The availability of new drugs for tardive dyskinesia (TD) means clinicians have an increased responsibility to proactively screen for the disorder and treat it when detected, Psych Congress cochair Rakesh Jain, MD, MPH, said.

DNA

Low-frequency and rare genetic variants may play a role in the development of tardive dyskinesia (TD), suggests a preliminary study published in European Neuropsychopharmacology.

blood test

An analysis of blood serum has identified differences between patients with tardive dyskinesia (TD) and people who have not developed the movement disorder.

NEW ORLEANS—Researchers have developed a new scale to measure the impacts tardive dyskinesia has on patients and their caregivers, according to a poster abstract presented at Psych Congress 2017.

Pages

Posters

Justin Barnes, PhD; Brandon Coleman, BS; Sylvie Stacy, MD; Tsao-Wei Liang, MD; Stanley Caroff, MD; Greg Salinas, PhD
Karen Anderson, MD; Mat Davis, PhD; Stewart Factor, DO; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Hubert Fernandez, MD
Benjamin Carroll, PharmD; Paul Juneau, MS; Debra Irwin, MD, MSPH
Gordon Loewen, PhD; Rosa Luo, EM; Evan Smith, BS; Grace Liang, PhD; Khodayar Farahmand, PharmD; Haig Bozigian, PhD; Christopher OкBrien, MD
Hubert Fernandez, MD; Mat Davis, PhD; Stewart Factor, DO; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Karen Anderson, MD

Pages